Intervention Review

You have free access to this content

Corticosteroids for treating nerve damage in leprosy

  1. Natasja HJ Van Veen1,*,
  2. Peter G Nicholls2,
  3. W Cairns S Smith3,
  4. Jan Hendrik Richardus1

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 15 APR 2009

Assessed as up-to-date: 16 JAN 2011

DOI: 10.1002/14651858.CD005491.pub2

Database Title

Additional Information

How to Cite

Van Veen NHJ, Nicholls PG, Smith WCS, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD005491. DOI: 10.1002/14651858.CD005491.pub2.

Author Information

  1. 1

    Erasmus Medical Center, Department of Public Health, Rotterdam, Netherlands

  2. 2

    University of Southampton, School of Health Sciences, Southampton, UK

  3. 3

    University of Aberdeen, Public Health, Aberdeen, UK

*Natasja HJ Van Veen, Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam, 3000 CA, Netherlands. n.vanveen@erasmusmc.nl. nhjvanveen@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 15 APR 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (60K)Standard (310K)Full (381K)
[Figure 1]
Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Corticosteroids versus placebo, Outcome 1 Change in sensory score after one year.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Corticosteroids versus placebo, Outcome 2 Proportion with sensory improvement after one year.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Corticosteroids versus placebo, Outcome 3 Change in motor score after one year.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Corticosteroids versus placebo, Outcome 4 Proportion with motor improvement after one year.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Corticosteroids versus placebo, Outcome 5 Proportion with serious adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 High dose versus low dose five-month course corticosteroids, Outcome 1 Proportion needing additional corticosteroids during twelve months.
[Analysis 3.1]
Analysis 3.1. Comparison 3 High dose five-month versus three-month course corticosteroids, Outcome 1 Proportion needing additional corticosteroids during twelve months.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Low dose versus short course corticosteroids, Outcome 1 Proportion needing additional corticosteroids during twelve months.
View Full Article (HTML) Summary (60K)Standard (310K)Full (381K)